AAC Clyde Space (AAC) remains an interesting avenue into the fast-growing low Earth orbital space se...
Permit appeals fall flat, final decision on 5 December Feasibility study and resource update coming ...
Redeye states that the Q3 report came in below our estimates on both sales and EBITDA.
Group net sales was EUR 31.2m in Q3 (Nordea est. EUR 31.
Investors House reported Q3 revenues of EUR 2.4m, 10% below our EUR 2.
Tillväxtmaskinen tuffar på EQL Pharma ökade nettoomsättningen med 43,0 procent i det andra kvartalet...
Redeye provides its comment on Mendus’ Q3 2024 report.
Redeye provides an update following SenzaGen’s Q3 2024 report.
Redeye comments on Lifeclean’s order from a defense authority in a European country.
Q3 sales EUR 44m (+5% y-o-y), order intake EUR 36m (-5% y-o-y) Margin improvements but slight declin...
Minor estimate changes in absolute terms Restructuring likely to carry full effect in H2'25e '25e-'2...
Sales -9% (-16% ex. M&A), EBITA 5.7% (8.8%), but vs.
Redeye provides its initial comments on Nanologica's Q3 report, which showed softer-than-expected sa...
Redeye updates its view on Acarix following its Q3 report, showing lower revenues than anticipated.
Operatively CapMan’s Q3 fell short of our expectations mainly due to negative fair value changes, wh...
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, bu...
We leave estimates relatively unchanged after Q3...
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board...
Redeye updates on G5 Entertainment post Q3-results which were weaker than expected.
NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated lat...
